Meeting Coverage
NANETS
North American Neuroendocrine Tumor Society
Long-term survival, cost-effectiveness examined in other studies
Latest NANETS Meeting Coverage
All patients with tumors <1 cm alive at 5 years without surgery
October 8, 2018
Mortality odds 70%-80% lower for all but stage I disease
October 6, 2018
Overall survival lengthened with salvage therapy
October 23, 2017
Identifies seven NET subtypes for those with uncertain diagnoses
October 22, 2017
177Lu-dotatate provides significant benefit for global health status and more
October 22, 2017
Treatment associated with objective tumor responses, encouraging PFS
October 22, 2017